Literature DB >> 1738004

Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus.

J R Backstrom1, C A Miller, Z A Tökés.   

Abstract

Three neutral proteinases from human hippocampal tissue have been identified and partially characterized using substrate gel electrophoresis. The proteinases showed activity when gelatin was used as the substrate, but had no detectable activity against casein. Based on the results of inhibition studies and the calcium requirements, it was concluded that the activities were due to calcium-dependent metalloproteinases. The apparent molecular weights were 130,000 (MP-130), 100,000 (MP-100), and 70,000 (MP-70). Half-maximal activities were observed with 20 microM Ca2+ for MP-130, 40 microM Ca2+ for MP-100, and 800 microM Ca2+ for MP-70. In the presence of Ca2+, Zn2+ reestablished the activities of the three metalloproteinases at a lower concentration than did either Co2+ or Mn2+. One millimolar Al3+ inhibited 67% of the MP-70 activity, but did not affect the MP-100 and MP-130 activities. An analysis of Alzheimer-affected hippocampal and control samples showed that the specific activity (in units per milligram of sodium dodecyl sulfate-soluble protein) of MP-70 varied less than the activities of MP-100 and MP-130 between the two groups. Although p-amino-phenylmercuric acetate (p-APMA) increased the activities of MP-70 by 70% in both groups of specimens, the resulting activities from Alzheimer samples were greater than those from control samples (p less than 0.01). A wide range of MP-100 specific activity was observed in both groups, and its mean activity was higher in Alzheimer-affected samples (p less than 0.05). Treatment with p-APMA increased the activity of MP-100 only 25% in both groups of tissue samples. MP-130 activity was detected predominantly in Alzheimer-affected hippocampal specimens, and treatment with p-APMA failed to increase its activity in both the control and the Alzheimer-affected specimens. The results demonstrate an elevated level of metalloproteinase activities, capable of degrading tissue matrix components, in the hippocampus from postmortem Alzheimer patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738004     DOI: 10.1111/j.1471-4159.1992.tb09352.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.

Authors:  B O Evert; I R Vogt; C Kindermann; L Ozimek; R A de Vos; E R Brunt; I Schmitt; T Klockgether; U Wüllner
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

3.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

4.  Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40).

Authors:  J R Backstrom; G P Lim; M J Cullen; Z A Tökés
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

Review 5.  A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease.

Authors:  Mark A Lovell
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer's disease.

Authors:  Charis Ringland; Jonas Elias Schweig; Daniel Paris; Ben Shackleton; Cillian E Lynch; Maxwell Eisenbaum; Michael Mullan; Fiona Crawford; Laila Abdullah; Corbin Bachmeier
Journal:  Neurobiol Aging       Date:  2020-07-03       Impact factor: 4.673

7.  Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican?

Authors:  G Perides; R A Asher; M W Lark; W S Lane; R A Robinson; A Bignami
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

8.  Increased activity of matrix metalloproteinase-2 in human glial and neuronal cell lines treated with HIV-1 gp41 peptides.

Authors:  Y H Chong; J Y Seoh; H K Park
Journal:  J Mol Neurosci       Date:  1998-04       Impact factor: 3.444

9.  Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells.

Authors:  T Yamada; K Miyazaki; N Koshikawa; M Takahashi; H Akatsu; T Yamamoto
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  Increased matrix metalloproteinase 9 activity in mild cognitive impairment.

Authors:  Martin A Bruno; Elliott J Mufson; Joanne Wuu; A Claudio Cuello
Journal:  J Neuropathol Exp Neurol       Date:  2009-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.